IGC Pharma (IGC) Retained Earnings (2011 - 2026)
IGC Pharma (IGC) posted quarterly Retained Earnings of -$127.3 million for Q1 2026, down 3541.08% year-over-year from $3.7 million in Q1 2025, and down 1.92% quarter-over-quarter from -$124.9 million in Q4 2025.
IGC Pharma (IGC) Retained Earnings (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Retained Earnings for 16 consecutive years, with -$127.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 3541.08% year-over-year to -$127.3 million; the TTM figure through Mar 2026 stood at -$127.3 million (down 3541.08% YoY), while the FY2026 annual figure was -$127.3 million, down 3541.08% from the prior year.
- Retained Earnings declined to -$127.3 million in Q1 2026 per IGC's latest filing, from -$124.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$3.0 million in Q1 2022 and bottomed at -$127.3 million in Q1 2026.
- Historically, Retained Earnings has averaged -$54.8 million across 5 years, with a median of -$4.9 million in 2025.
- Annual changes were most pronounced in 2025 — Retained Earnings surged 96.92% — and 2026, when it slumped 3541.08%.
- IGC Pharma's Retained Earnings stood at -$3.4 million in 2022, then gained by 0.15% to -$3.4 million in 2023, then slumped by 3391.65% to -$119.6 million in 2024, then slipped by 4.43% to -$124.9 million in 2025, then retreated by 1.92% to -$127.3 million in 2026.
- Business Quant data shows IGC's Retained Earnings at -$127.3 million in Q1 2026, -$124.9 million in Q4 2025, and -$4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | -127.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -127.29 Mn |
| Dec 31, 2025 | -124.89 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Jun 30, 2025 | -122.34 Mn |
| Mar 31, 2025 | -3.50 Mn |
| Dec 31, 2024 | -119.59 Mn |
| Sep 30, 2024 | -3.44 Mn |
| Jun 30, 2024 | -3.43 Mn |
| Mar 31, 2024 | -113.67 Mn |
| Dec 31, 2023 | -3.43 Mn |
| Sep 30, 2023 | -105.19 Mn |
| Jun 30, 2023 | -3.38 Mn |
| Mar 31, 2023 | -3.39 Mn |
| Dec 31, 2022 | -3.43 Mn |
| Sep 30, 2022 | -94.39 Mn |
| Jun 30, 2022 | -91.94 Mn |
| Mar 31, 2022 | -2.97 Mn |
| Dec 31, 2021 | -2.76 Mn |
| Sep 30, 2021 | -80.28 Mn |
| Jun 30, 2021 | -2.86 Mn |